IRIS
CONTE, BENEDETTA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 998
EU - Europa 682
NA - Nord America 585
SA - Sud America 100
AF - Africa 93
OC - Oceania 2
Totale 2.460
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 554
SG - Singapore 435
RU - Federazione Russa 370
HK - Hong Kong 171
CN - Cina 165
VN - Vietnam 103
ES - Italia 68
IT - Italia 68
BR - Brasile 67
BJ - Benin 59
DE - Germania 52
KR - Corea 40
FR - Francia 34
AT - Austria 22
CA - Canada 21
IN - India 19
UA - Ucraina 16
ZA - Sudafrica 16
AR - Argentina 14
PL - Polonia 12
GB - Regno Unito 11
BD - Bangladesh 10
FI - Finlandia 10
IQ - Iraq 8
JP - Giappone 8
NL - Olanda 7
VE - Venezuela 6
MX - Messico 5
EC - Ecuador 4
SE - Svezia 4
TN - Tunisia 4
AE - Emirati Arabi Uniti 3
CL - Cile 3
CO - Colombia 3
ID - Indonesia 3
JM - Giamaica 3
LB - Libano 3
PH - Filippine 3
PY - Paraguay 3
SY - Repubblica araba siriana 3
TR - Turchia 3
AU - Australia 2
DZ - Algeria 2
IL - Israele 2
KE - Kenya 2
KG - Kirghizistan 2
LT - Lituania 2
NP - Nepal 2
PK - Pakistan 2
PS - Palestinian Territory 2
TH - Thailandia 2
TW - Taiwan 2
AL - Albania 1
AM - Armenia 1
AO - Angola 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BF - Burkina Faso 1
BY - Bielorussia 1
CI - Costa d'Avorio 1
EG - Egitto 1
GA - Gabon 1
GM - Gambi 1
HU - Ungheria 1
JO - Giordania 1
KZ - Kazakistan 1
MA - Marocco 1
ML - Mali 1
MN - Mongolia 1
MW - Malawi 1
NG - Nigeria 1
OM - Oman 1
PR - Porto Rico 1
RO - Romania 1
SI - Slovenia 1
TT - Trinidad e Tobago 1
UZ - Uzbekistan 1
Totale 2.460
Salva come PNG Salva come JPEG
Città #
Singapore 189
San Jose 186
Hong Kong 170
Ashburn 83
Cotonou 59
Moscow 43
Seoul 38
Beijing 37
Ho Chi Minh City 35
Lauterbourg 33
Los Angeles 33
Buffalo 28
Hanoi 21
Assago 20
Falkenstein 16
Council Bluffs 12
New York 12
Nuremberg 12
Santa Clara 11
Chennai 10
Helsinki 10
Vienna 10
Munich 9
Orem 9
Redondo Beach 9
Chicago 8
Da Nang 8
Dallas 8
Johannesburg 8
Warsaw 8
Shanghai 7
São Paulo 7
Tokyo 7
Frankfurt am Main 6
Guangzhou 6
Montreal 6
Novara 6
Tianjin 6
Boston 5
Brembate di Sopra 5
Hải Dương 5
Milan 5
Toronto 5
Atlanta 4
Haiphong 4
Kyiv 4
Mumbai 4
Tornaco 4
Amsterdam 3
Belo Horizonte 3
Brooklyn 3
Buenos Aires 3
Caracas 3
Curitiba 3
Denver 3
Kingston 3
Ottawa 3
Phủ Lý 3
Poplar 3
Rio de Janeiro 3
San Francisco 3
Santiago 3
St Louis 3
Stockholm 3
Asunción 2
Baghdad 2
Baie-D'Urfé 2
Barnet 2
Bishkek 2
Camaiore 2
Cape Town 2
Carapicuíba 2
Changzhou 2
Dalian 2
Damascus 2
Guarulhos 2
Houston 2
Istanbul 2
Katowice 2
Manchester 2
Marcos Paz 2
Matino 2
Mexico City 2
Nairobi 2
Parauapebas 2
Phoenix 2
Quito 2
Quận Ba 2
Sarno 2
Secaucus 2
Torrelles de Llobregat 2
Tunis 2
Venice 2
Zhengzhou 2
Abidjan 1
Abuja 1
Aguascalientes 1
Almaty 1
Americana 1
Amman 1
Totale 1.345
Salva come PNG Salva come JPEG
Nome #
Frequency and spectrum of PIK3CA somatic mutations in breast cancer 103
TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy 89
Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trial 86
De novo Metastatic Breast Cancer Arising in Young Women: Review of the Current Evidence 83
Dose-dense adjuvant chemotherapy in HER2-positive early breast cancer patients before and after the introduction of trastuzumab: Exploratory analysis of the GIM2 trial 82
Circulating tumor DNA dynamics in advanced breast cancer treated with CDK4/6 inhibition and endocrine therapy 81
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation 75
Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer 74
Dose-dense adjuvant chemotherapy in early breast cancer patients: 15-year results of the Phase 3 Mammella InterGruppo (MIG)-1 study 74
Efficacy of adjuvant chemotherapy schedules for breast cancer according to body mass index: results from the phase III GIM2 trial 72
HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1 68
Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer 65
Adding a platinum agent to neoadjuvant chemotherapy for triple-negative breast cancer: the end of the debate 63
Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis 63
Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in breast cancer patients 63
Sex Hormones and Hormone Therapy during COVID-19 Pandemic: Implications for Patients with Cancer 62
Breast Cancer Surgery in the COVID-19 Pandemic: Validation of a Preventive Program for Patients and Health Care Workers 60
Update on the management of breast cancer during pregnancy 59
Anthracycline, taxane, and trastuzumab-based neoadjuvant chemotherapy in HER2-positive early breast cancer: phase II trial 57
HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis 56
A 14-gene B-cell immune signature in early-stage triple-negative breast cancer (TNBC): a pooled analysis of seven studies 54
T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study 53
Treatment-induced early menopause and the protective role of gonadotropin-releasing hormone agonists during chemotherapy 52
Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor-Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2-Based Therapy 52
Prospective study to optimize care and improve knowledge on ovarian function and/or fertility preservation in young breast cancer patients: Results of the pilot phase of the PREgnancy and FERtility (PREFER) study 49
Italian survey on managing immune checkpoint inhibitors in oncology during COVID-19 outbreak 49
Intrinsic subtypes and therapeutic decision-making in hormone receptor-positive/HER2-negative metastatic breast cancer with visceral crisis: A case report. 49
T-DM1 Efficacy in Patients With HER2-positive Metastatic Breast Cancer Progressing After a Taxane Plus Pertuzumab and Trastuzumab: An Italian Multicenter Observational Study 48
SNPs of aromatase predict long-term survival and aromatase inhibitor toxicity in patients with early breast cancer: a biomarker analysis of the GIM4 and GIM5 trials 48
Neoadjuvant endocrine therapy for luminal breast tumors: State of the art, challenges and future perspectives 46
Inclusion of Platinum Agents in Neoadjuvant Chemotherapy Regimens for Triple-Negative Breast Cancer Patients: Development of GRADE (Grades of Recommendation, Assessment, Development and Evaluation) Recommendation by the Italian Association of Medical Oncology (AIOM) 45
Linking tumor immune infiltration to enhanced longevity in recurrence-free breast cancer 44
Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis 43
Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in breast cancer patients 41
Treatment-induced early menopause and the protective role of gonadotropin-releasing hormone agonists during chemotherapy 39
Potential Mechanisms of Ovarian Protection with Gonadotropin-Releasing Hormone Agonist in Breast Cancer Patients: A Review 36
Prognostic value of intrinsic subtypes in hormone-receptor-positive metastatic breast cancer: systematic review and meta-analysis 36
Potential Mechanisms of Ovarian Protection with Gonadotropin-Releasing Hormone Agonist in Breast Cancer Patients: A Review 35
Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis 33
Management of young women with early breast cancer 33
Inclusion of Platinum Agents in Neoadjuvant Chemotherapy Regimens for Triple-Negative Breast Cancer Patients: Development of GRADE (Grades of Recommendation, Assessment, Development and Evaluation) Recommendation by the Italian Association of Medical Oncology (AIOM) 31
Management of young women with early breast cancer 30
Luteininzing hormone releasing hormones analogs in combination with tamoxifen for the adjuvant treatment of premenopausal women with hormone receptor positive breast cancer 26
Luteinizing hormone-releasing hormone analogs in combination with tamoxifen for the adjuvant treatment of premenopausal women with hormone receptor-positive breast cancer 25
Prospective study to optimize care and improve knowledge on ovarian function and/or fertility preservation in young breast cancer patients: Results of the pilot phase of the PREgnancy and FERtility (PREFER) study 24
Aromatase Inhibitors as Adjuvant Therapy in Early Breast Cancer: Insights into Toxicities and Their Management 14
Updating the Role of Carboplatin Added to Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: A Meta-Analysis 13
Navigating Cardiotoxicity in Immune Checkpoint Inhibitors: From Diagnosis to Long-Term Management 12
Comparative efficacy between real-world and randomized studies of palbociclib+endocrine therapy in HR-positive/HER2-negative metastatic breast cancer: systematic review and meta-analysis 9
Pembrolizumab and Paclitaxel in HR+/HER2- Breast Cancer with HER2-Enriched or Basal-Like Subtypes 8
null 6
Efficacy of anti-PD1 therapy in PD1-high mRNA tumors across multiple cancer types: results from cohort 1 and cohort 2 of the phase II SOLTI-1904 ACROPOLI trial 6
null 5
Prevalence and clinical impact of germline pathogenic variants in breast cancer: a descriptive large single-center study 4
null 4
null 4
null 2
Totale 2.543
Salva come PNG Salva come JPEG
Categoria #
all - tutte 9.292
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 9.292
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2024/2025733 0 0 0 87 28 90 63 62 171 82 25 125
2025/20261.810 108 73 151 126 284 117 327 273 217 134 0 0
Totale 2.543